Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines (Q35625036)

9 August 2017

1 reference

title

Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines (English)

1 reference

9 August 2017

1

Kenneth H Eckels

1 reference

9 August 2017

Robert Putnak

2

1 reference

PubMed ID

14714438

9 August 2017

language of work or name

1 reference

1 January 2003

1 reference

Advances in Virus Research

9 August 2017

1 reference

9 August 2017

61

1 reference

9 August 2017

395-418

1 reference

Antigenic and genetic variations among Japanese encephalitis virus strains belonging to genotype 1.

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Side-effects with Japanese encephalitis vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Current status of flavivirus vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

A new vaccine against tick-borne encephalitis: initial trial in man including a dose-response study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

From the World Health Organization. Development of dengue and Japanese encephalitis vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Flavivirus genome organization, expression, and replication

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Protective efficacy in mice of a secreted form of recombinant dengue-2 virus envelope protein produced in baculovirus infected insect cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Analysis of C-terminally truncated dengue 2 and dengue 3 virus envelope glycoproteins: processing in insect cells and immunogenic properties in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Immunization of monkeys with baculovirus-dengue type-4 recombinants containing envelope and nonstructural proteins: evidence of priming and partial protection.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Dengue type-2 virus envelope protein made using recombinant baculovirus protects mice against virus challenge.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Tick-borne encephalitis: development of a paediatric vaccine. A controlled, randomized, double-blind and multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Dengue and dengue hemorrhagic fever

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Epitope model of tick-borne encephalitis virus envelope glycoprotein E: analysis of structural properties, role of carbohydrate side chain, and conformational changes occurring at acidic pH.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Adjuvants--a balance between toxicity and adjuvanticity

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

A randomized phase II study of a new tick-borne encephalitis vaccine using three different doses and two immunization regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Preparation of a highly purified vaccine against tick-borne encephalitis by continuous flow zonal ultracentrifugation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Recombinant and virion-derived soluble and particulate immunogens for vaccination against tick-borne encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

1 reference

7 January 2021

Protection against Japanese encephalitis by inactivated vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

A recombinant particulate antigen of Japanese encephalitis virus produced in stably-transformed cells is an effective noninfectious antigen and subunit immunogen

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Development of new vaccines against dengue fever and Japanese encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Particulate vaccine candidate for Japanese encephalitis induces long-lasting virus-specific memory T lymphocytes in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Generation and Characterization of a Mammalian Cell Line Continuously Expressing Japanese Encephalitis Virus Subviral Particles

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Immunogenicity and reactogenicity of a highly purified vaccine against tick‐borne encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Definition of an epitope on NS3 recognized by human CD4+ cytotoxic T lymphocyte clones cross-reactive for dengue virus types 2, 3, and 4.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Immunogenicity and protective efficacy of the current inactivated Japanese encephalitis vaccine against different Japanese encephalitis virus strains

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Use of live and inactivated vaccines in the control of West Nile fever in domestic geese.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Adverse reactions to Japanese encephalitis vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Systemic immediate-type reactions to gelatin included in Japanese encephalitis vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Two patterns of systemic immediate-type reactions to Japanese encephalitis vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

A purified inactivated Japanese encephalitis virus vaccine made in Vero cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Dengue virus envelope glycoprotein can be secreted from insect cells as a fusion with the maltose-binding protein

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Affinity-purified dengue-2 virus envelope glycoprotein induces neutralizing antibodies and protective immunity in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Expression of the dengue virus structural proteins in Pichia pastoris leads to the generation of virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

The use of yellow fever virus modified by in vitro cultivation for human immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Phylogenetic analysis suggests only one serotype of Japanese encephalitis virus

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

The epidemiology of Japanese encephalitis: prospects for prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Induction of protective immunity against Dengue virus type 2: comparison of candidate live attenuated and recombinant vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Immunity to St. Louis encephalitis virus by sequential immunization with recombinant vaccinia and baculovirus derived PrM/E proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Immunization of mice against West Nile virus with recombinant envelope protein

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

1 reference

7 January 2021

Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Carboxy-terminally truncated dengue virus envelope glycoproteins expressed on the cell surface and secreted extracellularly exhibit increased immunogenicity in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Dengue-1 virus envelope glycoprotein gene expressed in recombinant baculovirus elicits virus-neutralizing antibody in mice and protects them from virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

Murine immunoglobulin G subclass responses following immunization with live dengue virus or a recombinant dengue envelope protein

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2803%2961010-9

7 January 2021

10.1016/S0065-3527(03)61010-9

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

14714438